MA45189A - Nouveaux dérivés hétérocycliques utiles en tant qu'inhibiteurs de shp2 - Google Patents

Nouveaux dérivés hétérocycliques utiles en tant qu'inhibiteurs de shp2

Info

Publication number
MA45189A
MA45189A MA045189A MA45189A MA45189A MA 45189 A MA45189 A MA 45189A MA 045189 A MA045189 A MA 045189A MA 45189 A MA45189 A MA 45189A MA 45189 A MA45189 A MA 45189A
Authority
MA
Morocco
Prior art keywords
derivatives useful
heterocyclic derivatives
new heterocyclic
shp2 inhibitors
shp2
Prior art date
Application number
MA045189A
Other languages
English (en)
Inventor
Jinlong Bai
Jie Chu
Panliang Gao
Di Kang
Cunbo Ma
Xiaoyan Pei
Chunwei Wen
Xinping Wu
Original Assignee
Jacobio Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jacobio Pharmaceuticals Co Ltd filed Critical Jacobio Pharmaceuticals Co Ltd
Publication of MA45189A publication Critical patent/MA45189A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MA045189A 2016-06-07 2017-06-07 Nouveaux dérivés hétérocycliques utiles en tant qu'inhibiteurs de shp2 MA45189A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2016085122 2016-06-07

Publications (1)

Publication Number Publication Date
MA45189A true MA45189A (fr) 2019-04-10

Family

ID=60578379

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045189A MA45189A (fr) 2016-06-07 2017-06-07 Nouveaux dérivés hétérocycliques utiles en tant qu'inhibiteurs de shp2

Country Status (23)

Country Link
US (1) US10858359B2 (fr)
EP (2) EP4108659A1 (fr)
JP (3) JP6751203B2 (fr)
KR (5) KR20210141778A (fr)
CN (3) CN109311848B (fr)
AU (1) AU2017276457B2 (fr)
CA (1) CA3026784A1 (fr)
CY (1) CY1125042T1 (fr)
DK (1) DK3464272T3 (fr)
EA (3) EA202092441A1 (fr)
ES (1) ES2908801T3 (fr)
HR (1) HRP20220251T1 (fr)
HU (1) HUE057838T2 (fr)
LT (1) LT3464272T (fr)
MA (1) MA45189A (fr)
MX (3) MX388576B (fr)
PH (1) PH12018550202A1 (fr)
PL (1) PL3464272T3 (fr)
PT (1) PT3464272T (fr)
RS (1) RS62987B1 (fr)
SG (2) SG11201810983PA (fr)
SI (1) SI3464272T1 (fr)
WO (1) WO2017211303A1 (fr)

Families Citing this family (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11466017B2 (en) 2011-03-10 2022-10-11 Board Of Regents, The University Of Texas System Heterocyclic inhibitors of PTPN11
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
EP3463343B1 (fr) 2016-05-31 2022-03-23 Board of Regents, The University of Texas System Inhibiteurs hétérocycliques de ptpn11
EA202092441A1 (ru) * 2016-06-07 2021-05-21 Джакобио Фармасьютикалс Ко., Лтд. Новые гетероциклические производные, применимые в качестве ингибиторов shp2
PT3468972T (pt) 2016-06-14 2020-08-21 Novartis Ag Compostos e composições para inibir a atividade da shp2
KR102598895B1 (ko) 2016-07-12 2023-11-07 레볼루션 메디슨즈, 인크. 다른자리 입체성 shp2 억제제로서의 2,5-이치환 3-메틸 피라진 및 2,5,6-3치환 3-메틸 피라진
US11529347B2 (en) 2016-09-22 2022-12-20 Relay Therapeutics, Inc. SHP2 phosphatase inhibitors and methods of use thereof
TWI848901B (zh) 2016-10-24 2024-07-21 美商傳達治療有限公司 Shp2磷酸酶抑制劑及其使用方法
CA3051054A1 (fr) 2017-01-23 2018-07-26 Revolution Medicines, Inc. Composes de pyridine utilises en tant qu'inhibiteurs allosteriques de shp2
MX2019008695A (es) 2017-01-23 2019-09-11 Revolution Medicines Inc Compuestos biciclicos como inhibidores alostericos de shp2.
US10988466B2 (en) * 2017-03-23 2021-04-27 Jacobio Pharmaceuticals Co., Ltd. Heterocyclic derivatives useful as SHP2 inhibitors
WO2018218133A1 (fr) 2017-05-26 2018-11-29 Relay Therapeutics, Inc. Dérivés de pyrazolo[3,4-b]pyrazine en tant qu'inhibiteurs de la phosphatase shp2
JP7356414B2 (ja) 2017-09-07 2023-10-04 レヴォリューション・メディスンズ，インコーポレイテッド がんを治療するためのｓｈｐ２阻害剤組成物および方法
CN118684652A (zh) 2017-09-11 2024-09-24 克鲁松制药公司 SHP2的八氢环戊二烯并[c]吡咯别构抑制剂
US11701354B2 (en) 2017-09-29 2023-07-18 D. E. Shaw Research, Llc Pyrazolo[3,4-b]pyrazine derivatives as SHP2 phosphatase inhibitors
JP2020536881A (ja) 2017-10-12 2020-12-17 レヴォリューション・メディスンズ，インコーポレイテッド アロステリックｓｈｐ２阻害剤としてのピリジン、ピラジンおよびトリアジン化合物
EP3724189B1 (fr) 2017-12-15 2023-10-04 Revolution Medicines, Inc. Composés polycycliques comme inhibiteurs allosteriques de la shp2
AU2019222026B2 (en) 2018-02-13 2022-05-12 Shanghai Blueray Biopharma Co., Ltd. Pyrimidine-fused cyclic compound, preparation method therefor and application thereof
MX2020008754A (es) 2018-03-02 2020-12-07 Otsuka Pharma Co Ltd Compuestos farmaceuticos.
RU2020133727A (ru) 2018-03-21 2022-04-21 Сучжоу Пухе Биофарма Ко., Лтд. Ингибиторы shp2 и их применение
AU2019240299B2 (en) * 2018-03-21 2023-06-22 D.E. Shaw Research, Llc SHP2 phosphatase inhibitors and methods of use thereof
US12138263B2 (en) 2018-03-21 2024-11-12 Relay Therapeutics, Inc. Pyrazolo[3,4-b]pyrazine SHP2 phosphatase inhibitors and methods of use thereof
CA3096535A1 (fr) 2018-04-10 2019-10-17 Revolution Medicines, Inc. Compositions d'inhibiteurs de shp2 et methodes de traitement du cancer
SG11202010822SA (en) 2018-05-02 2020-11-27 Navire Pharma Inc Substituted heterocyclic inhibitors of ptpn11
CN110143949A (zh) * 2018-05-09 2019-08-20 北京加科思新药研发有限公司 可用作shp2抑制剂的新型杂环衍生物
EA202190342A1 (ru) 2018-07-24 2021-07-22 Тайхо Фармасьютикал Ко., Лтд. Гетеробициклические соединения для ингибирования активности shp2
PL3833670T3 (pl) * 2018-08-10 2024-08-19 Navire Pharma, Inc. Pochodne 6-(4-amino-3-metylo-2-oksa-8-azaspiro[4.5]dekan-8-ylo)-3-(2,3-dichlorofenylo)-2-metylopirymidyn-4(3h)-onu oraz powiązane związki jako inhibitory ptpn11 (shp2) do leczenia raka
SG11202102679QA (en) 2018-09-18 2021-04-29 Nikang Therapeutics Inc Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors
US20210393623A1 (en) 2018-09-26 2021-12-23 Jacobio Pharmaceuticals Co., Ltd. Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors
CA3113379A1 (fr) * 2018-09-29 2020-04-02 Novartis Ag Procede de fabrication d'un compose pour inhiber l'activite de shp2
WO2020065452A1 (fr) * 2018-09-29 2020-04-02 Novartis Ag Fabrication de composés et de compositions pour inhiber l'activité de shp2
US11179397B2 (en) 2018-10-03 2021-11-23 Gilead Sciences, Inc. Imidazopyrimidine derivatives
JP2022508651A (ja) 2018-10-08 2022-01-19 レヴォリューション・メディスンズ，インコーポレイテッド 癌を処置するためのｓｈｐ２阻害剤組成物および方法
TW202028183A (zh) * 2018-10-10 2020-08-01 大陸商江蘇豪森藥業集團有限公司 含氮雜芳類衍生物調節劑、其製備方法和應用
EP3867238B1 (fr) 2018-10-17 2023-06-07 Array BioPharma Inc. Inhibiteurs de protéine tyrosine phosphatase
CN117143079A (zh) * 2018-11-06 2023-12-01 上海奕拓医药科技有限责任公司 一种螺芳环化合物及其应用
TW202039498A (zh) 2018-11-30 2020-11-01 大陸商上海拓界生物醫藥科技有限公司 嘧啶並五員氮雜環類衍生物、其製備方法及其在醫藥上的應用
JP2022509724A (ja) 2018-12-05 2022-01-24 ミラティ セラピューティクス， インコーポレイテッド 組み合わせ療法
AU2020232616A1 (en) 2019-03-01 2021-09-09 Revolution Medicines, Inc. Bicyclic heterocyclyl compounds and uses thereof
JP2022522777A (ja) 2019-03-01 2022-04-20 レボリューション メディシンズ インコーポレイテッド 二環式ヘテロアリール化合物及びその使用
CN111647000B (zh) 2019-03-04 2021-10-12 勤浩医药（苏州）有限公司 吡嗪类衍生物及其在抑制shp2中的应用
CN113795483B (zh) 2019-03-07 2024-12-31 默克专利有限公司 作为shp2拮抗剂的甲酰胺-嘧啶衍生物
PE20220141A1 (es) 2019-04-02 2022-01-27 Array Biopharma Inc Inhibidores de la proteina tirosina fosfatasa
CA3127475A1 (fr) 2019-04-08 2020-10-15 Merck Patent Gmbh Derives de pyrimidinone utilises en tant qu'antagonistes de shp2
TWI826690B (zh) 2019-05-23 2023-12-21 美商基利科學股份有限公司 經取代之烯吲哚酮化物及其用途
JP7295283B2 (ja) 2019-06-25 2023-06-20 ギリアード サイエンシーズ， インコーポレイテッド Ｆｌｔ３ｌ－ｆｃ融合タンパク質及び使用方法
US20220380385A1 (en) * 2019-06-28 2022-12-01 Tuojie Biotech(Shanghai) Co., Ltd. Pyrimidine five-membered nitrogen heterocyclic derivative, preparation method thereof and pharmaceutical use thereof
CN111704611B (zh) * 2019-07-25 2022-01-14 上海凌达生物医药有限公司 一类芳基螺环类shp2抑制剂化合物、制备方法和用途
EP3772513A1 (fr) * 2019-08-09 2021-02-10 C.N.C.C.S. S.c.a.r.l. Collezione Nazionale Dei Composti Chimici e Centro Screening Inhibiteurs d'shp2
GB201911928D0 (en) * 2019-08-20 2019-10-02 Otsuka Pharma Co Ltd Pharmaceutical compounds
WO2021043077A1 (fr) * 2019-09-06 2021-03-11 四川科伦博泰生物医药股份有限公司 Composé de pyrazine substituée et procédé de préparation correspondant et son utilisation
AU2020354475A1 (en) 2019-09-24 2022-05-05 Relay Therapeutics, Inc. SHP2 phosphatase inhibitors and methods of making and using the same
CN112724145A (zh) * 2019-10-14 2021-04-30 杭州雷索药业有限公司 用于抑制shp2活性的吡嗪衍生物
CA3153501A1 (fr) 2019-10-18 2021-04-22 Forty Seven, Inc. Polytherapies pour le traitement de syndromes myelodysplasiques et de la leucemie myeloide aigue
MY209360A (en) 2019-10-31 2025-07-03 Forty Seven Llc Anti-cd47 and anti-cd20 based treatment of blood cancer
MX2022005357A (es) 2019-11-04 2022-06-02 Revolution Medicines Inc Inhibidores de ras.
CN114867735A (zh) 2019-11-04 2022-08-05 锐新医药公司 Ras抑制剂
JP2022553858A (ja) 2019-11-04 2022-12-26 レボリューション メディシンズ インコーポレイテッド Ｒａｓ阻害剤
KR20220100903A (ko) 2019-11-08 2022-07-18 레볼루션 메디슨즈, 인크. 이환식 헤테로아릴 화합물 및 이의 용도
TWI778443B (zh) 2019-11-12 2022-09-21 美商基利科學股份有限公司 Mcl1抑制劑
EP4065231A1 (fr) 2019-11-27 2022-10-05 Revolution Medicines, Inc. Inhibiteurs de ras covalents et leurs utilisations
PE20230376A1 (es) 2019-12-24 2023-03-06 Carna Biosciences Inc Compuestos moduladores de la diacilglicerol quinasa
TW202140011A (zh) 2020-01-07 2021-11-01 美商銳新醫藥公司 Shp2抑制劑給藥和治療癌症的方法
CN113135910A (zh) * 2020-01-19 2021-07-20 北京诺诚健华医药科技有限公司 嘧啶-4(3h)-酮类杂环化合物、其制备方法及其在医药学上的应用
KR20220142484A (ko) 2020-02-14 2022-10-21 조운스 테라퓨틱스, 인크. Ccr8에 결합하는 항체 및 융합 단백질, 및 이의 용도
CA3173358A1 (fr) 2020-02-28 2021-09-02 Novartis Ag Combinaison pharmaceutique triple comprenant du dabrafenib, un inhibiteur d'erk et un inhibiteur de shp2
CN115362149B (zh) * 2020-04-26 2024-05-14 贝达药业股份有限公司 Shp2抑制剂及其组合物和应用
CN115279749B (zh) * 2020-04-30 2024-05-10 贝达药业股份有限公司 Shp2抑制剂及其组合物和应用
JP7564888B2 (ja) 2020-05-01 2024-10-09 ギリアード サイエンシーズ， インコーポレイテッド Ｃｄ７３阻害性２，４－ジオキソピリミジン化合物
CN113754683A (zh) 2020-06-05 2021-12-07 上海奕拓医药科技有限责任公司 同位素取代的螺芳环化合物及其应用
BR112022025550A2 (pt) 2020-06-18 2023-03-07 Revolution Medicines Inc Métodos para retardar, prevenir e tratar resistência adquirida aos inibidores de ras
JP2023530838A (ja) * 2020-06-22 2023-07-20 スーチュアン・コールン－バイオテック・バイオファーマシューティカル・カンパニー・リミテッド 置換されたピラジン化合物、当該化合物を含む医薬組成物、及びその使用
JP7729870B2 (ja) 2020-07-08 2025-08-26 ノバルティス アーゲー Ｓｈｐ２の活性を阻害するための化合物及び組成物の製造
KR20230081726A (ko) 2020-09-03 2023-06-07 레볼루션 메디슨즈, 인크. Shp2 돌연변이가 있는 악성 종양을 치료하기 위한 sos1 억제제의 용도
TW202227460A (zh) 2020-09-15 2022-07-16 美商銳新醫藥公司 Ｒａｓ抑制劑
TW202241885A (zh) 2020-12-22 2022-11-01 大陸商上海齊魯銳格醫藥研發有限公司 Ｓｏｓ１抑制劑及其用途
EP4039685A1 (fr) 2021-02-08 2022-08-10 Irbm S.P.A. Inhibiteurs azabicycliques de shp2
WO2022199611A1 (fr) * 2021-03-23 2022-09-29 上海海雁医药科技有限公司 Dérivé de cétone substitué par un hétérocycle, et composition et son utilisation médicinale
EP4067358A1 (fr) 2021-04-02 2022-10-05 C.N.C.C.S. S.c.a.r.l. Collezione Nazionale Dei Composti Chimici e Centro Screening Dérivés de (s)-1-(5-((pyridin-3-yl)thio)pyrazin-2-yl)-4'h,6'h-spiro[pipéridine-4,5'-pyrrolo[1,2-b]pyrazol]-4'-amine et composés similaires en tant qu'inhibiteurs de shp2 pour le traitement par ex. du cancer
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
JP2024516450A (ja) 2021-05-05 2024-04-15 レボリューション メディシンズ インコーポレイテッド 共有結合性ｒａｓ阻害剤及びその使用
US12252497B2 (en) 2021-05-05 2025-03-18 Revolution Medicines, Inc. Ras inhibitors
MX2023013062A (es) 2021-05-05 2023-11-15 Huyabio Int Llc Monoterapia con inhibidores de shp2 y usos de la misma.
MX2023013085A (es) 2021-05-05 2023-11-16 Revolution Medicines Inc Inhibidores de ras.
WO2022235817A1 (fr) 2021-05-05 2022-11-10 Huabio International, Llc Polythérapies comprenant des inhibiteurs de shp2 et des inhibiteurs de pd-1
EP4328228A4 (fr) * 2021-05-13 2025-04-30 Shanghai Institute of Materia Medica, Chinese Academy of Sciences Composé hétérocyclique pour inhiber l'activité de shp2, son procédé de préparation et son utilisation
WO2022245671A1 (fr) 2021-05-18 2022-11-24 Gilead Sciences, Inc. Méthodes d'utilisation de protéines de fusion flt3l-fc
TW202313041A (zh) 2021-06-09 2023-04-01 瑞士商諾華公司 包含達拉菲尼、曲美替尼和shp2抑制劑之三重藥物組合
US11999733B2 (en) 2021-06-23 2024-06-04 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
US11926628B2 (en) 2021-06-23 2024-03-12 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
US11932634B2 (en) 2021-06-23 2024-03-19 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
TW202317100A (zh) 2021-06-23 2023-05-01 瑞士商諾華公司 包含ｋｒａｓ ｇ１２ｃ抑制劑的藥物組合及其用於治療癌症之用途
AU2022299051B2 (en) 2021-06-23 2025-03-13 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
KR102682323B1 (ko) * 2021-07-09 2024-07-09 주식회사 카나프테라퓨틱스 Shp2 억제제 및 이의 용도
CN113461538A (zh) * 2021-07-12 2021-10-01 无锡双启科技有限公司 一种2-氯-3-溴苯胺的制备方法
JP2024532374A (ja) 2021-09-01 2024-09-05 ノバルティス アーゲー Ｔｅａｄ阻害剤を含む医薬品組み合わせ物及び癌の治療のためのその使用
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
WO2023076983A1 (fr) 2021-10-28 2023-05-04 Gilead Sciences, Inc. Dérivés de pyridine-3(2h)-one
CN118201941A (zh) 2021-10-29 2024-06-14 吉利德科学公司 Cd73化合物
US20230203202A1 (en) 2021-12-08 2023-06-29 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and 5t4
WO2023107954A1 (fr) 2021-12-08 2023-06-15 Dragonfly Therapeutics, Inc. Anticorps ciblant 5t4 et leurs utilisations
CN118488946A (zh) 2021-12-22 2024-08-13 吉利德科学公司 Ikaros锌指家族降解剂及其用途
KR20240125012A (ko) 2021-12-22 2024-08-19 길리애드 사이언시즈, 인코포레이티드 이카로스 아연 핑거 패밀리 분해제 및 이의 용도
US20250109118A1 (en) * 2021-12-28 2025-04-03 Js Innomed Holdings Ltd. Heterocyclic compounds as shp2 inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
JP2025510572A (ja) 2022-03-08 2025-04-15 レボリューション メディシンズ インコーポレイテッド 免疫不応性肺癌を治療するための方法
CN118369323A (zh) * 2022-03-10 2024-07-19 捷思英达控股有限公司 作为shp2抑制剂的杂环化合物、包括该杂环化合物的组合物、及其使用方法
MX2024011279A (es) 2022-03-17 2024-09-25 Gilead Sciences Inc Degradadores de dedos de zinc de la familia ikaros y usos de estos.
CA3254506A1 (fr) 2022-03-24 2023-09-28 Gilead Sciences, Inc. Polythérapie pour le traitement de cancers exprimant trop -2
TWI876305B (zh) 2022-04-05 2025-03-11 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
CN119487038A (zh) 2022-04-21 2025-02-18 吉利德科学公司 Kras g12d调节化合物
TW202404581A (zh) 2022-05-25 2024-02-01 美商醫肯納腫瘤學公司 Ｍｅｋ抑制劑及其用途
AU2023285116A1 (en) 2022-06-10 2024-12-19 Revolution Medicines, Inc. Macrocyclic ras inhibitors
AU2023298558A1 (en) 2022-07-01 2024-12-19 Gilead Sciences, Inc. Cd73 compounds
JP2025528836A (ja) 2022-08-17 2025-09-02 ツリーライン バイオサイエンシズ インコーポレイテッド ピリドピリミジンＫＲａｓ阻害剤
WO2024064668A1 (fr) 2022-09-21 2024-03-28 Gilead Sciences, Inc. POLYTHÉRAPIE ANTICANCÉREUSE PAR RAYONNEMENT IONISANT FOCAL ET PERTURBATION CD47/SIRPα
EP4345101A1 (fr) 2022-09-29 2024-04-03 Irbm S.P.A. Dérivés d'azole utilisés en tant qu'inhibiteurs de shp2
CN117917410A (zh) 2022-10-21 2024-04-23 上海领泰生物医药科技有限公司 pan-KRAS降解剂及其制备方法和应用
TW202423442A (zh) 2022-10-21 2024-06-16 大陸商上海領泰生物醫藥科技有限公司 Kras g12d降解劑及其製備方法與應用
CN115677660B (zh) * 2022-10-27 2024-05-03 中国药科大学 苯基脲类化合物及其制备方法、用途和药物组合物
WO2024137852A1 (fr) 2022-12-22 2024-06-27 Gilead Sciences, Inc. Inhibiteurs de prmt5 et leurs utilisations
EP4647433A1 (fr) * 2023-01-05 2025-11-12 Kanaph Therapeutics Inc. Inhibiteur de shp2 et ses utilisations
WO2024206858A1 (fr) 2023-03-30 2024-10-03 Revolution Medicines, Inc. Compositions pour induire une hydrolyse de ras gtp et leurs utilisations
WO2024211712A1 (fr) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Composés macrocycliques condensés en tant qu'inhibiteurs de ras
WO2024211663A1 (fr) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Composés macrocycliques condensés en tant qu'inhibiteurs de ras
US20240383922A1 (en) 2023-04-11 2024-11-21 Gilead Sciences, Inc. KRAS Modulating Compounds
WO2024216016A1 (fr) 2023-04-14 2024-10-17 Revolution Medicines, Inc. Formes cristallines d'un inhibiteur de ras
TW202448897A (zh) 2023-04-14 2024-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑之結晶形式、含有其之組合物及其使用方法
KR20250175331A (ko) 2023-04-21 2025-12-16 길리애드 사이언시즈, 인코포레이티드 Prmt5 억제제 및 이의 용도
WO2024229406A1 (fr) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Polythérapie pour une maladie ou un trouble lié à ras
WO2025006720A1 (fr) 2023-06-30 2025-01-02 Gilead Sciences, Inc. Composés modulateurs de kras
WO2025024811A1 (fr) 2023-07-26 2025-01-30 Gilead Sciences, Inc. Inhibiteurs de parp7
WO2025024663A1 (fr) 2023-07-26 2025-01-30 Gilead Sciences, Inc. Inhibiteurs de parp7
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025034919A1 (fr) 2023-08-08 2025-02-13 Quanta Therapeutics, Inc. Polythérapies avec des modulateurs de kras
WO2025036475A1 (fr) * 2023-08-17 2025-02-20 Jacobio Pharmaceuticals Co., Ltd. Combinaison pharmaceutique et son utilisation
US20250101042A1 (en) 2023-09-08 2025-03-27 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2025054530A1 (fr) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Dérivés polycycliques contenant une pyrimidine utilisés comme composés de modulation de kras g12d
WO2025064848A1 (fr) 2023-09-21 2025-03-27 Treeline Biosciences, Inc. Inhibiteurs de kras de type dihydropyranopyrimidines spirocycliques
WO2025080946A2 (fr) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Inhibiteurs de ras
WO2025081291A1 (fr) * 2023-10-16 2025-04-24 Canwell Biotech Limited Dérivés de benzo [c] [1, 2] oxaborol-1(3h)-ol utilisés comme inhibiteurs de shp2, compositions et méthodes associées
WO2025096589A1 (fr) 2023-11-03 2025-05-08 Gilead Sciences, Inc. Inhibiteurs de prmt5 et leurs utilisations
WO2025106901A1 (fr) 2023-11-17 2025-05-22 Quanta Therapeutics, Inc. Polythérapies anticancéreuses avec un modulateur de kras et un inhibiteur de la voie rtk-mapk
WO2025137507A1 (fr) 2023-12-22 2025-06-26 Regor Pharmaceuticals, Inc. Inhibiteurs de sos1 et leurs utilisations
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025171296A1 (fr) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Inhibiteurs de ras
WO2025240847A1 (fr) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Inhibiteurs de ras
WO2025245127A1 (fr) 2024-05-21 2025-11-27 Treeline Biosciences, Inc. Inhibiteurs de dihydropyranopyrimidine kras spirocycliques
US20250376484A1 (en) 2024-05-21 2025-12-11 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (fr) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Compositions thérapeutiques et procédés de gestion d'effets liés au traitement
WO2026006747A1 (fr) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Inhibiteurs de ras

Family Cites Families (174)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3377826B2 (ja) 1993-05-06 2003-02-17 ヘキスト・アクチェンゲゼルシャフト 液晶組成物に使用するための新規化合物
ATE284690T1 (de) 1995-10-31 2005-01-15 Lilly Co Eli Antithrombotische diamine
CA2361734A1 (fr) 1999-01-26 2000-10-12 Andre Rosowsky Composes pharmaceutiquement actifs et procedes d'utilisation
US7375125B2 (en) 1999-08-04 2008-05-20 Ore Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
DE60126997T2 (de) 2000-10-20 2007-10-25 Eisai R&D Management Co., Ltd. Stickstoff-enthaltende aromatische ringverbindungen zur behandlung von tumorerkrankungen
JP2006503796A (ja) 2001-12-21 2006-02-02 バイエル・フアーマシユーチカルズ・コーポレーシヨン ピリダジンまたはピリジン誘導体を含んでなる抗−脈管形成組み合わせ療法
JP4467307B2 (ja) 2002-02-22 2010-05-26 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー ５−ｈｔ受容体アンタゴニストとしてのピリジルスルホン誘導体
DE10246657A1 (de) 2002-10-07 2004-04-15 Merck Patent Gmbh Chirales Phenolderivat, dieses enthaltendes Flüssigkristallmedium, Verfahren zur Herstellung eines Flüssigkristallmediums und elektrooptische Flüssigkristallanzeige
ES2369720T5 (es) 2002-11-18 2014-11-06 Chemocentryx, Inc. Arilsulfonamidas
SE0203712D0 (sv) 2002-12-13 2002-12-13 Astrazeneca Ab Novel compounds
DE602004015254D1 (de) 2003-02-07 2008-09-04 Janssen Pharmaceutica Nv Hiv-inhibierende1,2,4-triazine
US20040248850A1 (en) 2003-02-11 2004-12-09 Kemia, Inc. Compounds for the treatment of HIV infection
GB2400101A (en) 2003-03-28 2004-10-06 Biofocus Discovery Ltd Compounds capable of binding to the active site of protein kinases
WO2004099158A1 (fr) 2003-04-30 2004-11-18 Ricerca Biosciences, Llc. N-oxydes monocycliques utilises comme antagonistes des proteines bcl-2
US7393873B2 (en) 2003-07-02 2008-07-01 Merck & Co., Inc. Arylsulfonamide derivatives
EP1654264A1 (fr) 2003-07-08 2006-05-10 AstraZeneca AB Derives de spiro [1-azabicyclo [2.2.2]octan-3,5 '-oxazolidin -2' -one] possedant une affinite avec le recepteur d´ acetylcholine nicotinique alpha7
AU2004278382B2 (en) 2003-09-30 2008-09-18 Amgen Inc. Vanilloid receptor ligands and their use in treatments
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
TW200528459A (en) 2004-01-06 2005-09-01 Achillion Pharmaceuticals Inc Azabenzofuran substituted thioureas; inhibitors of viral replication
JP5283336B2 (ja) 2004-01-12 2013-09-04 ワイエム・バイオサイエンシズ・オーストラリア・ピーティーワイ・リミテッド 選択的キナーゼ阻害剤
US7435830B2 (en) 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
US7435831B2 (en) 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
US7687502B2 (en) * 2004-03-23 2010-03-30 Banyu Pharmaceutical Co., Ltd. Substituted quinazoline or pyridopyrimidine derivative
JP4865702B2 (ja) 2004-05-03 2012-02-01 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド サイトカイン阻害剤
BRPI0512535A (pt) 2004-06-24 2008-03-25 Incyte Corp compostos de piperidinas n-substituìdas, suas composições e métodos de modulações
US20070043057A1 (en) 2005-02-09 2007-02-22 Threshold Pharmaceuticals, Inc. Lonidamine analogs
US8153640B2 (en) 2004-10-29 2012-04-10 Tibotec Pharmaceuticals Ltd. HIV inhibiting bicyclic pyrimdine derivatives
WO2006063010A2 (fr) 2004-12-08 2006-06-15 Nuada, Llc Composes et procedes d'utilisation
GB0428082D0 (en) 2004-12-22 2005-01-26 Welcome Trust The Ltd Therapeutic compounds
JP2008525487A (ja) 2004-12-23 2008-07-17 マリンクロッド・インコーポレイテッド 蛍光ピラジン誘導体および腎機能評価におけるその使用方法
US7622583B2 (en) 2005-01-14 2009-11-24 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2
EP1850681B1 (fr) 2005-02-04 2019-12-18 Firmenich Incorporated Composes comportant des groupes fonctionnels d'heteroaryle lies et leur utilisation en tant que nouveaux modificateurs de saveur, agents gustatifs et exhausteurs de gout umami pour des compositions alimentaires
WO2006087305A1 (fr) 2005-02-16 2006-08-24 Neurosearch A/S Derives aryle diazabicycliques et utilisation medicale
WO2007046867A2 (fr) 2005-05-19 2007-04-26 Xenon Pharmaceuticals Inc. Derives de piperidine et leurs utilisations comme agents therapeutiques
ES2574014T3 (es) 2005-05-30 2016-06-14 Msd K.K. Derivado de piperidina novedoso
JP2007013804A (ja) 2005-07-01 2007-01-18 Mitsubishi Electric Corp 属性指定通信方法および通信装置
US7851474B2 (en) * 2005-08-02 2010-12-14 Neurogen Corporation Dipiperazinyl ketones and related analogues
EP2388258A1 (fr) 2005-10-19 2011-11-23 Grünenthal GmbH Nouveaux ligands du récepteur vanilloide et leur utilisation dans la production de médicaments
WO2007057742A2 (fr) 2005-11-18 2007-05-24 Pfizer Products Inc. Nouveaux derives de piperazinone
WO2007063868A1 (fr) 2005-11-29 2007-06-07 Toray Industries, Inc. Derive d'arylmethylene uree et utilisation de celui-ci
AU2006328551A1 (en) 2005-12-21 2007-06-28 Janssen Pharmaceutica N.V. Substituted pyrazinone derivatives as alpha2c-adrenoreceptor antagonists
WO2007084728A2 (fr) 2006-01-19 2007-07-26 Abbott Laboratories 2-imino-benzimidazoles
EP1991544B1 (fr) 2006-01-30 2018-08-15 vTv Therapeutics LLC Derives d'imidazole a substitution, compositions et procedes d'utilisation en tant qu'inhibiteurs de ptpase
JP2009529047A (ja) 2006-03-07 2009-08-13 アレイ バイオファーマ、インコーポレイテッド ヘテロ二環系ピラゾール化合物およびその使用
JP2009534356A (ja) 2006-04-20 2009-09-24 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 薬剤として用いるための置換ピラジノン誘導体
JP2009537602A (ja) 2006-05-22 2009-10-29 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 薬剤として用いるための置換ピラジノン誘導体
US7838523B2 (en) 2006-09-11 2010-11-23 Cgi Pharmaceuticals, Inc. Certain substituted amides, method of making, and method of use thereof
PE20081370A1 (es) 2006-09-11 2008-11-28 Cgi Pharmaceuticals Inc Determinadas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas
ES2344128T3 (es) 2006-10-04 2010-08-18 F. Hoffmann-La Roche Ag Derivados de pirazina-2-carboxamida como moduladores de receptores cb2.
DE102007018150A1 (de) 2007-04-16 2008-10-23 Grünenthal GmbH VR1-Rezeptor-Liganden und µ-Opioid-Rezeptor-Liganden zur Behandlung von Schmerz
EP2120573A4 (fr) 2007-02-12 2011-05-25 Merck Sharp & Dohme Dérivés de la pipéridine
US8338437B2 (en) 2007-02-28 2012-12-25 Methylgene Inc. Amines as small molecule inhibitors
BRPI0808523A2 (pt) 2007-03-01 2014-08-19 Novartis Vaccines & Diagnostic Inibidores de pim cinase e métodos de seu uso
CN101687040A (zh) 2007-03-01 2010-03-31 马林克罗特公司 整合光活性的小分子及其用途
WO2008112674A1 (fr) 2007-03-12 2008-09-18 Irm Llc Composés et compositions comme inhibiteurs de l'activité du récepteur cannabinoïde 1
JP2010538094A (ja) 2007-09-06 2010-12-09 アレイ バイオファーマ、インコーポレイテッド チロシンキナーゼ阻害剤としてのピラゾロピリジン類
WO2009036066A1 (fr) 2007-09-10 2009-03-19 Curis, Inc. Inhibiteurs du récepteur du facteur de croissance endothélial vasculaire (vegfr) contenant une fraction de liaison au zinc
JP5465177B2 (ja) 2007-09-20 2014-04-09 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｇｐｒ１１９活性のモジュレーターとしての化合物および組成物
MX2010003849A (es) 2007-10-18 2010-04-27 Boehringer Ingelheim Int Antagonistas de cgrp.
EP2211864A1 (fr) 2007-10-24 2010-08-04 Merck Sharp & Dohme Corp. Antagonistes des canaux calciques de type t à base d'amide de pyrazinyle
US20110027264A1 (en) 2008-02-29 2011-02-03 Xianhai Huang Gamma secretase modulators for the treatment of alzheimer's disease
JP5530422B2 (ja) 2008-04-07 2014-06-25 アムジエン・インコーポレーテツド 細胞周期阻害薬としてのｇｅｍ−二置換およびスピロ環式アミノピリジン／ピリミジン
CL2009001064A1 (es) 2008-05-07 2009-10-09 Galapagos Nv Compuestos derivados de imidazol-pirazina o triazol-pirazina fusionados, inhibidores de mapkapk5; composicion farmaceutica que comprende dichos compuestos; y uso para preparar un medicamento destinado al tratamiento de inflamacion, especialmente en la artritis reumatoide.
WO2009142732A2 (fr) 2008-05-20 2009-11-26 Cephalon, Inc. Dérivés pyridazinone substitués comme ligands des récepteurs de l'histamine-3 (h<sb>3</sb>)
AU2009271414A1 (en) 2008-06-20 2010-01-21 Metabolex, Inc. Aryl GPR119 agonists and uses thereof
US8685980B2 (en) 2008-08-22 2014-04-01 Novartis Ag Pyrrolopyrimidine compounds and their uses
JP5731978B2 (ja) 2008-09-26 2015-06-10 インテリカイン， エルエルシー 複素環キナーゼ阻害剤
WO2010077992A1 (fr) 2008-12-17 2010-07-08 Amgen Inc. Composés aminopyridines et carboxypyridines en tant que inhibiteurs de phosphodiestérase 10
JP5599815B2 (ja) 2008-12-19 2014-10-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規化合物
BRPI0923592A2 (pt) 2008-12-25 2016-01-26 Taisho Pharmaceutical Co Ltd composto
US8076291B2 (en) 2009-01-22 2011-12-13 Unigene Laboratories Inc. Treatment for obesity
WO2010086613A1 (fr) 2009-01-30 2010-08-05 Betagenon Ab Composés utiles en tant qu'inhibiteurs tel que ampk
JP5765239B2 (ja) 2009-03-13 2015-08-19 アドヴィナス・セラピューティックス・リミテッド 置換縮合ピリミジン化合物
BR112012000370B1 (pt) 2009-07-08 2019-04-16 Baltic Bio Ab Compostos úteis como medicamentos
CN102753177A (zh) 2009-08-17 2012-10-24 纪念斯隆-凯特琳癌症中心 热休克蛋白结合化合物、组合物以及其制备和使用方法
JP2013503846A (ja) 2009-09-01 2013-02-04 ファイザー・インク ベンズイミダゾール誘導体
MX2012004078A (es) 2009-10-09 2012-07-25 Irm Llc Compuestos y composiciones como moduladores de la actividad de gpr119.
US8759377B2 (en) 2009-11-23 2014-06-24 Vanderbilt University Substituted dioxopiperidines and dioxopyrrolidines as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
BR112012014164A2 (pt) 2009-12-14 2016-05-17 Merck Patent Gmbh inibidores da esfingosina quinase
CN104530079B (zh) 2009-12-18 2017-10-20 北京凯因科技股份有限公司 C型肝炎病毒复制的新型抑制剂
ES2550667T3 (es) 2010-02-18 2015-11-11 Vtv Therapeutics Llc Derivados de fenilheteroarilo y métodos de uso de los mismos
US20130035336A1 (en) 2010-04-13 2013-02-07 Novartis Ag Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (cdk4/6) inhibitor for treating cancer
DK2563780T3 (en) 2010-04-29 2015-07-27 Univ Edinburgh 3,3-DISUBSTITUEREDE- (8-aza-bicyclo [3.2.1] oct-8-yl) - [5- (1H-pyrazol-4-yl) -thiophene-3-yl] -METHANONER as inhibitors of 11 ( BETA) -HSD1
US20110312996A1 (en) 2010-05-17 2011-12-22 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
EP3318561B1 (fr) 2010-05-26 2021-12-22 Sunovion Pharmaceuticals Inc. Composés hétéroaryles et procédés d'utilisation correspondants
US8791136B2 (en) 2010-07-29 2014-07-29 Rigel Pharmaceuticals, Inc. Substituted pyridine, pyridazine, pyrazine and pyrimidine compounds and methods for using the same
JP2013230986A (ja) 2010-08-25 2013-11-14 Kyorin Pharmaceutical Co Ltd 新規ヒダントイン誘導体及びそれらを有効成分とする医薬
CN102432598A (zh) 2010-09-29 2012-05-02 江苏恒瑞医药股份有限公司 三环化合物、其制备方法及其在医药上的应用
WO2012068106A2 (fr) * 2010-11-15 2012-05-24 Exelixis, Inc. Benxazépines en tant qu'inhibiteurs de pi3k/mtor et leurs procédés d'utilisation et de fabrication
GB201020161D0 (en) 2010-11-26 2011-01-12 Almac Discovery Ltd Pharmaceutical compounds
AU2011343039B2 (en) 2010-12-14 2017-03-02 Electrophoretics Limited Casein kinase 1delta (CK1delta) inhibitors
US8987271B2 (en) 2010-12-22 2015-03-24 Eutropics Pharmaceuticals, Inc. 2,2′-biphenazine compounds and methods useful for treating disease
US20120184572A1 (en) 2011-01-13 2012-07-19 Metabolex, Inc. Aryl gpr119 agonists and uses thereof
JP2014515029A (ja) 2011-04-29 2014-06-26 アイカーン・スクール・オブ・メディシン・アト・マウント・シナイ キナーゼ阻害剤
US9586928B2 (en) 2011-05-16 2017-03-07 The Scripps Research Institute Modulators of the nuclear hormone receptor ROR
US20120316182A1 (en) * 2011-06-10 2012-12-13 Calcimedica, Inc. Compounds that modulate intracellular calcium
EP2554544A1 (fr) 2011-08-01 2013-02-06 Almirall, S.A. Dérivés de pyridin-2(1h)-one en tant qu'inhibiteurs de JAK
WO2013039851A1 (fr) 2011-09-12 2013-03-21 Mallinckrodt Llc Agents optiques permettant d'obtenir des images de métalloprotéases matricielles et de les visualiser
BR112014013925B1 (pt) 2011-12-12 2022-02-22 Receptos Llc Compostos moduladores do receptor de glp-1 e composição e combinação farmacêutica compreendendo os ditos compostos
JP6396216B2 (ja) 2012-02-22 2018-09-26 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 液晶媒体
GB201204985D0 (en) 2012-03-21 2012-05-02 Genentech Inc Compounds
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
JP6175673B2 (ja) 2012-04-25 2017-08-09 ラクオリア創薬株式会社 Ｔｔｘ−ｓ遮断薬としてのアミド誘導体
WO2013167633A1 (fr) 2012-05-09 2013-11-14 Basf Se Composés d'acrylamide pour la lutte contre des animaux nuisibles invertébrés
EP2867232B1 (fr) 2012-06-27 2018-08-08 F.Hoffmann-La Roche Ag Composés de 5-azaindazole et procédés d'utilisation
WO2014000178A1 (fr) 2012-06-27 2014-01-03 Merck Sharp & Dohme Corp. Dérivés de sulfamide et leurs méthodes d'utilisation permettant d'améliorer la pharmacocinétique d'un médicament
ES2750640T3 (es) 2012-08-16 2020-03-26 Scripps Research Inst Ligandos opioides kappa novedosos
JOP20130273B1 (ar) 2012-09-11 2021-08-17 Genzyme Corp مثبطات انزيم (سينثاز) غلوكوسيل سيراميد
WO2014074761A2 (fr) * 2012-11-09 2014-05-15 Glaxosmithkline Llc Nouveaux composés en tant qu'inhibiteurs de diacylglycérol acyltransférase
WO2014144847A2 (fr) 2013-03-15 2014-09-18 G1 Therapeutics, Inc. Traitements épargnant hspc pour la prolifération cellulaire anormale rb positive
EP2970116A1 (fr) 2013-03-15 2016-01-20 F. Hoffmann-La Roche AG Dérivés d'aryl sulfamide et de sulfamate comme modulateurs de rorc
WO2014184074A1 (fr) 2013-05-15 2014-11-20 Basf Se Composés de n-(tétrazol-5-yl)- et n-(triazol-5-yl)hétarylcarboxamide substitués et leur utilisation en tant qu'herbicides
WO2014184014A1 (fr) 2013-05-15 2014-11-20 Basf Se Composés de n-(1,2,5-oxadiazol-3-yl)carboxamide et leur utilisation en tant qu'herbicides
GB201309508D0 (en) 2013-05-28 2013-07-10 Redx Pharma Ltd Compounds
EA030857B1 (ru) 2013-06-11 2018-10-31 Селджин Интернэшнл Ii Сарл Новые модуляторы рецептора glp-1
WO2015003094A2 (fr) 2013-07-03 2015-01-08 Indiana University Research & Technology Corporation Inhibiteurs de shp2 et méthodes de traitement de maladies auto-immunes et associées à la glomérulonéphrite à l'aide d'inhibiteurs de shp2
CN104341386A (zh) * 2013-07-23 2015-02-11 中国科学院上海药物研究所 一类芳基杂环小分子化合物、其衍生物及其制备方法和用途
JPWO2015016206A1 (ja) 2013-07-30 2017-03-02 武田薬品工業株式会社 複素環化合物
EP3027625B1 (fr) 2013-07-31 2018-05-30 Merck Sharp & Dohme Corp. Derives spiro-fusionnes de piperidine utiles dans le traitement, entre autres, de l'hypertension et de l' insuffisance cardiaque aiguë ou chronique
WO2015048547A2 (fr) 2013-09-26 2015-04-02 Rigel Pharmaceuticals, Inc. Procédé d'utilisation de composés activant l'ampk et biomarqueurs de l'ampk
US10463662B2 (en) 2013-10-08 2019-11-05 Qing-Bin Lu Non-platinum-based anti-cancer compounds for use in targeted chemotherapy
CN105939998B (zh) 2013-10-21 2019-04-16 默克专利有限公司 用作btk抑制剂的杂芳基化合物及其用途
US10131841B2 (en) 2013-12-16 2018-11-20 Merck Patent Gmbh Liquid-crystalline medium
WO2015091420A1 (fr) 2013-12-19 2015-06-25 Bayer Pharma Aktiengesellschaft Utilisation de dérivés de bipipéridinyle substitués comme antagonistes des alpha-2c-adrénorécepteurs
CN105899491B (zh) 2014-01-17 2019-04-02 诺华股份有限公司 用于抑制shp2活性的1-哒嗪-/三嗪-3-基-哌(-嗪)/啶/吡咯烷衍生物及其组合物
WO2015107494A1 (fr) * 2014-01-17 2015-07-23 Novartis Ag Dérivés de 1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine et compositions les contenant pour l'inhibition de l'activité de shp2
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
MA39337B1 (fr) 2014-02-14 2019-11-29 Takeda Pharmaceuticals Co Modulateurs de pyrazines de gpr6
US10000469B2 (en) 2014-03-25 2018-06-19 Duke University Heat shock protein 70 (hsp-70) receptor ligands
DK3129374T3 (en) 2014-04-07 2019-04-08 Netherlands Translational Res Center B V (5,6-dihydro) pyrimido [4,5-e] INDOLIZINER
RU2016149804A (ru) 2014-05-23 2018-06-26 Ф. Хоффманн-Ля Рош Аг Производные бензолсульфонамида и их применение в качестве модуляторов орфанного рецептора y, связанного с ретиноевой кислотой
WO2016015605A1 (fr) 2014-07-26 2016-02-04 Sunshine Lake Pharma Co., Ltd. Composés en tant que petites molécules inhibitrices de la cdk et leurs utilisations
WO2016022644A1 (fr) 2014-08-06 2016-02-11 Merck Sharp & Dohme Corp. Antagonistes hétérocycliques des récepteurs cgrp
WO2016022645A1 (fr) 2014-08-06 2016-02-11 Merck Sharp & Dohme Corp. Antagonistes hétérocycliques du récepteur du cgrp
EP2985334B1 (fr) 2014-08-15 2018-06-20 Merck Patent GmbH Milieu liquide cristallin
SG11201701683XA (en) * 2014-09-05 2017-04-27 Celgene Quanticel Res Inc Inhibitors of lysine specific demethylase-1
WO2016040449A1 (fr) 2014-09-10 2016-03-17 Raze Therapeutics, Inc. Inhibiteurs de la 3-phosphoglycérate déshydrogénase) et leurs utilisations
EP3262049B1 (fr) 2015-02-27 2022-07-20 Nimbus Lakshmi, Inc. Inhibiteurs de tyk2 et leurs utilisations
EP3269715B1 (fr) 2015-03-11 2020-05-13 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Dérivé de 2-hydrogène-pyrazole substitué servant de médicament anticancéreux
JP2018509448A (ja) 2015-03-25 2018-04-05 ノバルティス アーゲー 組合せ医薬
AR104020A1 (es) 2015-06-04 2017-06-21 Kura Oncology Inc Métodos y composiciones para inhibir la interacción de menina con proteínas mill
HK1246593A1 (zh) 2015-06-04 2018-09-14 Kura Oncology, Inc. 用於抑制menin蛋白与mll蛋白的相互作用的方法及组合物
EP3310771B1 (fr) 2015-06-19 2020-07-22 Novartis AG Composés et compositions pour l'inhibition de l'activité de shp2
CN107922388B (zh) * 2015-06-19 2020-12-29 诺华股份有限公司 用于抑制shp2活性的化合物和组合物
ES2741746T3 (es) 2015-06-19 2020-02-12 Novartis Ag Compuestos y composiciones para inhibir la actividad de SHP2
RU2604047C1 (ru) 2015-07-10 2016-12-10 Фортис Аксис, Закрытое Акционерное Общество Массажёр для воздействия на мышцы спины трех отделов позвоночника
IL257743B (en) 2015-09-17 2022-08-01 Marvin J Miller Benzyl amine-containing heterocyclic compounds and compositions useful against mycobacterial infection
WO2017114351A1 (fr) 2015-12-27 2017-07-06 Chongqing Fochon Pharmaceutical Co., Ltd. Inhibiteurs de certaines protéines kinases
WO2017156397A1 (fr) 2016-03-11 2017-09-14 Board Of Regents, The University Of Texas Sysytem Inhibiteurs hétérocycliques de ptpn11
US10570141B2 (en) 2016-03-25 2020-02-25 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Substituted pyrrolopyrimidine CDK inhibitor, pharmaceutical composition containing same and use thereof
CN107286150B (zh) 2016-04-11 2020-07-07 中国科学院上海有机化学研究所 N-杂环类化合物、其中间体、制备方法、药物组合物和应用
EP3463343B1 (fr) 2016-05-31 2022-03-23 Board of Regents, The University of Texas System Inhibiteurs hétérocycliques de ptpn11
EA202092441A1 (ru) * 2016-06-07 2021-05-21 Джакобио Фармасьютикалс Ко., Лтд. Новые гетероциклические производные, применимые в качестве ингибиторов shp2
PT3468972T (pt) 2016-06-14 2020-08-21 Novartis Ag Compostos e composições para inibir a atividade da shp2
KR102598895B1 (ko) 2016-07-12 2023-11-07 레볼루션 메디슨즈, 인크. 다른자리 입체성 shp2 억제제로서의 2,5-이치환 3-메틸 피라진 및 2,5,6-3치환 3-메틸 피라진
EP3290412A1 (fr) 2016-08-31 2018-03-07 Università degli Studi di Siena Inhibiteurs des nucléocapsides du vih-1
US11529347B2 (en) 2016-09-22 2022-12-20 Relay Therapeutics, Inc. SHP2 phosphatase inhibitors and methods of use thereof
WO2018089433A1 (fr) 2016-11-08 2018-05-17 Navitor Pharmaceuticals, Inc. Inhibiteurs de mtorc phényle et leurs utilisations
JP2020503352A (ja) 2017-01-03 2020-01-30 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−３−イル酢酸誘導体
CA3048340A1 (fr) * 2017-01-10 2018-07-19 Novartis Ag Combinaison pharmaceutique comprenant un inhibiteur d'alk et un inhibiteur de shp2
CA3051590A1 (fr) * 2017-01-25 2018-08-02 Indiana University Research And Technology Corporation Prophylaxie et traitement de la leucemie myeloide aigue
US10988466B2 (en) * 2017-03-23 2021-04-27 Jacobio Pharmaceuticals Co., Ltd. Heterocyclic derivatives useful as SHP2 inhibitors
US12428423B2 (en) 2017-04-01 2025-09-30 Shengke Pharmaceuticals (Jiangsu) Ltd. 1H-imidazo[4,5-h]quinazoline compound as protein kinase inhibitor
CN110891569A (zh) 2017-07-12 2020-03-17 范德堡大学 毒蕈碱性乙酰胆碱受体m4的拮抗剂
JP2020536881A (ja) 2017-10-12 2020-12-17 レヴォリューション・メディスンズ，インコーポレイテッド アロステリックｓｈｐ２阻害剤としてのピリジン、ピラジンおよびトリアジン化合物
EP3697759B1 (fr) 2017-10-20 2025-12-31 Vanderbilt University Antagonistes du récepteur muscarinique de l'acétylcholine m4
US11279707B2 (en) 2017-12-22 2022-03-22 Dana-Farber Cancer Institute, Inc. NEK inhibitors and methods of use
US10988477B2 (en) 2018-01-29 2021-04-27 Merck Patent Gmbh GCN2 inhibitors and uses thereof
CN111867581B (zh) 2018-01-29 2023-12-26 默克专利股份有限公司 Gcn2抑制剂及其用途
US11426422B2 (en) 2018-01-30 2022-08-30 Research Development Foundation SHP2 inhibitors and methods of use thereof
KR20200141436A (ko) 2018-02-08 2020-12-18 엔요 파마 융합된 티오펜 유도체 및 이의 용도
MX2020008754A (es) 2018-03-02 2020-12-07 Otsuka Pharma Co Ltd Compuestos farmaceuticos.
EP3768272B1 (fr) 2018-03-21 2025-07-30 Xibin Liao Inhibiteurs de jak

Also Published As

Publication number Publication date
CA3026784A1 (fr) 2017-12-14
CN112250670B (zh) 2021-06-08
JP2022153616A (ja) 2022-10-12
EP3464272A4 (fr) 2019-04-24
ES2908801T3 (es) 2022-05-04
MX388576B (es) 2025-03-20
EA201990001A1 (ru) 2019-05-31
US20190127378A1 (en) 2019-05-02
EA202092441A1 (ru) 2021-05-21
CN109311848B (zh) 2022-02-01
CN112250670A (zh) 2021-01-22
KR20210141778A (ko) 2021-11-23
MX2018015297A (es) 2019-08-12
HUE057838T2 (hu) 2022-06-28
SG10202110874TA (en) 2021-11-29
WO2017211303A1 (fr) 2017-12-14
AU2017276457B2 (en) 2019-10-03
MX2021015074A (es) 2022-01-18
EP4108659A1 (fr) 2022-12-28
EP3464272B1 (fr) 2021-12-08
EA202092442A2 (ru) 2021-06-30
KR20230109185A (ko) 2023-07-19
KR102218333B1 (ko) 2021-02-22
SI3464272T1 (sl) 2022-05-31
PL3464272T3 (pl) 2022-03-28
AU2017276457A1 (en) 2019-01-24
CN109311848A (zh) 2019-02-05
CN114539273A (zh) 2022-05-27
EA202092442A3 (ru) 2021-08-31
PH12018550202A1 (en) 2019-10-21
JP2019521181A (ja) 2019-07-25
KR20220124275A (ko) 2022-09-13
SG11201810983PA (en) 2019-01-30
KR20210019607A (ko) 2021-02-22
DK3464272T3 (da) 2022-02-21
EP3464272A1 (fr) 2019-04-10
JP2020189868A (ja) 2020-11-26
LT3464272T (lt) 2022-03-10
PT3464272T (pt) 2022-03-11
CY1125042T1 (el) 2023-03-24
KR20190015756A (ko) 2019-02-14
JP6751203B2 (ja) 2020-09-02
MX2021015073A (es) 2022-01-18
HRP20220251T1 (hr) 2022-04-29
US10858359B2 (en) 2020-12-08
RS62987B1 (sr) 2022-03-31

Similar Documents

Publication Publication Date Title
MA49013A (fr) Nouveaux dérivés hétérocycliques utiles en tant qu&#39;inhibiteurs de shp2
MA45189A (fr) Nouveaux dérivés hétérocycliques utiles en tant qu&#39;inhibiteurs de shp2
MA47125A (fr) Dérivés de pyrazole en tant qu&#39;inhibiteurs de malt1
MA47123A (fr) Dérivés de benzooxazole en tant qu&#39;mmunomodulateurs
EP3416964A4 (fr) Dérivés de carboxamide utiles en tant qu&#39;inhibiteurs de rsk
MA46981A (fr) Dérivés de benzimidazole en tant qu&#39;inhibiteurs de bromodomaine
MA51878A (fr) Composés d&#39;aminothiazole en tant qu&#39;inhibiteurs de c-kit
MA40774A (fr) Dérivés de diaryle-urée en tant qu&#39;inhibiteurs de kinase p38
MA45153A (fr) Dérivés de carbonucléosides substitués utiles en tant qu&#39;agents anticancéreux
MA46339A (fr) Dérivés de cyanopyrrolidine ayant une activité en tant qu&#39;inhibiteurs de l&#39;usp 30
MA43169A (fr) Composés hétérocycliques utilisés en tant qu&#39;inhibiteurs de pi3k-gamma
MA42659A (fr) Dérivés hétéroaryle utilisés en tant qu&#39;inhibiteurs de parp
MA53150A (fr) Composés de benzimidazole en tant qu&#39;inhibiteurs de c-kit
MA45244A (fr) Pyridines substituées utilisées en tant qu&#39;inhibiteurs de dnmt1
MA53352A (fr) Dérivés de pyridin-2-(1h)-one-quinolinone en tant qu&#39;inhibiteurs d&#39;isocitrate déshydrogénase
MA55194A (fr) Composés hétérocycliques en tant qu&#39;immunomodulateurs
MA41140A (fr) Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu&#39;inhibiteurs de la parg
MA47086A (fr) Dérivés de dihydropyrimidine-carboxamide bicycliques utilisés en tant qu&#39;inhibiteurs de rho-kinase
MA54567A (fr) Pyridine et composés de pyridimine en tant qu&#39;inhibiteurs de pi3k-gamma
MA44498A (fr) Dérivés d&#39;indoline substituée utilisés en tant qu&#39;inhibiteurs de la réplication du virus de la dengue
MA42592A (fr) Utilisation de dérivés de 2-(pyrazolopyridin-3-yl) pyrimidine en tant qu&#39;inhibiteurs de jak
EP2970119A4 (fr) Nouveaux dérivés d&#39;indole utiles en tant qu&#39;agents antidiabétiques
MA44502A (fr) Dérivés d&#39;indole substitués utilisés en tant qu&#39;inhibiteurs de réplication du virus de la dengue
MA46878A (fr) Composés de benzodiazolium en tant qu&#39;inhibiteurs d&#39;enac
MA41341A (fr) Dérivés indole utilisés en tant qu&#39;inhibiteurs de la réplication du virus de la dengue